Clinical trial · Interventional
A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers
Advanced Metastatic Non-small Cell Lung Cancer Patients Aged or PS Score 2 Points for First Line Application Pemetrexed/Carboplatin Chemotherapy Regimens Sequential Pemetrexed Single Drug Maintenance Treatment of Clinical Research and Related Predictive Biomarkers of Exploratory Research
NCT01860508CI-TRIAL-00011227unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PFS
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pemetrexed /carboplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- pemetrexed
- interventionNames
- Drug: pemetrexed /carboplatin
Primary outcomes (1)
- measure
- PFS
- timeFrame
- from the first cycle of treatment (day one) to two month after the last cycle
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: .≥65 years or PS 2 * Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small cell lung cancer * Patients received no chemical therapy or only received targeted therapy,and there is evidence show the patent is PD * Presence of at least one index lesion measurable by CT scan or MRI * leucocyte ≥ 3.5×109/L * neutrophil ≥ 1.5×109/L * platelet ≥ 80×109/L * Hemoglobin ≥ 9g/L * ALT and AST ≤ 2.5×ULN ,Tbil≤ 1.5×ULN * BUN≤ 1.5×ULN * Signed written informed consent Exclusion Criteria: * squamous carcinoma or small cell lung cancer * Patients were allergic to pemetrexed * Patients received chemotherapy before * Uncontrolled acute infection .Uncontrolled pleural effusion * Severe symptomatic heart disease * Severe infection or metabolic disfunction * Patients with other malignant tumor * Uncontrolled brain metastases * Patients have accepted other clinical trials * Female patients during their pregnant and lactation period, or patients without contraception * Mental disorientation of disorder * Glucocorticoids taboo
References
Publications (1)
- DERIVEDZhao X, Yu H, Zhao J, Wu X, Sun S, Luo Z, Wang H, Qiao J, Chang J, Wang J. Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer. Oncotarget. 2017 Sep 23;8(49):86384-86394. doi: 10.18632/oncotarget.21186. eCollection 2017 Oct 17. PMID 29156802